Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

September 19, 2025

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Filipa Lynce, MD, and Rita Nanda, MD, discuss recent clinical trial and real-world data for antibody-drug conjugates (ADCs) used to treat triple-negative breast cancer (TNBC).

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Develop evidence-based strategies for integrating ADCs in the management of patients with metastatic TNBC

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Faculty:

Filipa Lynce, MD

Assistant Professor of Medicine
Harvard Medical School
Director, Inflammatory Breast Center
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Adviser: AstraZeneca, Daiichi Sankyo, Eli Lilly, Pfizer; Grant/Research Funding: AstraZeneca, Gilead, IDEAYA, Incyte, Merck, Zentalis; Executive Role: Alliance Foundation Trials.

Rita Nanda, MD

Associate Professor of Medicine
Director, Breast Oncology Program
University of Chicago Medicine
Chicago, IL

Disclosures: Advisory Board: Arvinas, AstraZeneca, Daiichi Sankyo, Exact Sciences, GE, Gilead, Guardant Health, Lilly, Merck, Moderna, Novartis, OBI, Pfizer, Sanofi, Seagen, Stemline, Summit Therapeutics; Research Funding: Arvinas, AstraZeneca, Bristol Myers Squibb, Corcept Therapeutics, Genentech/Roche, Gilead, GSK, Merck, Novartis, OBI Pharma, Pfizer, Relay, Seattle Genetics, Sun Pharma, Taiho.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including clinical trial data on TROP2-targeting ADCs, go to https://www.gotoper.com/courses/dissecting-clinical-trial-and-real-world-data-for-adcs-in-tnbc.

Release Date

September 19, 2025

Expiration Date

September 19, 2026

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.